JPRN-UMIN000002533
Completed
未知
autologous hematopoietic stem cell transplantation followed by reduced intensity allogeneic stem cell transplantation for relatively young patients with multiple myeloma - auto-allo HSCT for multiple myeloma
The university of Tokyo Hospital,department of hematology and oncology0 sites20 target enrollmentNovember 1, 2009
Conditionsmultiple myeloma
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- multiple myeloma
- Sponsor
- The university of Tokyo Hospital,department of hematology and oncology
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\.Patients who recall approval 2\.When stem cell source becomes not available 3\.Patients with another severe disease 4\.Patients who had received chemotherapy for maligancies other than multipul myeloma 5\.Patients who is recognized as inadaptable for this trial
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Stem cell transplantation in diffuse cutaneous systemic sclerosis: upfront therapy or rescue therapy after failure of immunosuppressantsDiffuse cutaneous systemic sclerosis according to the ACR/EULAR criteriaMedDRA version: 20.0Level: SOCClassification code: 10021428Term: Immune system disorders Class: 4Therapeutic area: Diseases [C] - Immune System Diseases [C20]CTIS2023-505877-34-00niversity Medical Center Utrecht88
Not yet recruiting
Not Applicable
pfront autologous hematopoietic stem cell transplantation versus immunosuppressive medication in early diffuse cutaneous systemic sclerosis: an international multicentre, open-label, randomized con-trolled trialSystemic SclerosisNL-OMON26075niversity Medical Centre Utrecht120
Recruiting
Phase 3
pfront autologous hematopoietic stem cell transplantation versus immunosuppressive medication in early diffuse cutaneous systemic sclerosis: an international multicentre, open-label, randomized controlled trialdiffuse cutaneous systemic sclerosisscleroderma10010761NL-OMON52909niversitair Medisch Centrum Utrecht60
Active, not recruiting
Phase 1
Stem cell transplantation in diffuse cutaneous systemic sclerosis: upfront therapy or rescue therapy after failure of immunosuppressants?Diffuse cutaneous systemic sclerosis according to the ACR/EULAR criteriaTherapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2019-004718-32-NLMC Utrecht120
Recruiting
Phase 2
Autologous Stem Cell Transplant in Multiple SclerosisMultiple SclerosisNeurological - Multiple sclerosisACTRN12622000536763St Vincent's Hospital, Sydney30